Risultati di ricerca
Bert Vogelstein (born 1949) is director of the Ludwig Center, Clayton Professor of Oncology and Pathology and a Howard Hughes Medical Institute investigator at The Johns Hopkins Medical School and Sidney Kimmel Comprehensive Cancer Center.
Bert Vogelstein, M.D., was the first scientist to elucidate the molecular basis of a common human cancer. In particular, he and his colleagues have demonstrated that colorectal tumors result from the gradual accumulation of genetic alterations in specific oncogenes and tumor suppressor genes.
Bert Vogelstein, MD. Research Interests. Our group has studied the genetics of human cancer for 40 years and has played a major role in elucidating the following principles governing the pathogenesis of human neoplasia. (i) Human tumors represent the expansion of a single transformed cell.
- vogelbe@jhmi.edu
- 410-955-8878
- 410-955-0548
- Clayton Professor
Genetic alterations during colorectal-tumor development. B Vogelstein, ER Fearon, SR Hamilton, SE Kern, AC Preisinger, ... New England Journal of Medicine 319 (9), 525-532. , 1988.
23 mar 2017 · Strategies for winning the wars on cancer. Ludwig Johns Hopkins Co-director Bert Vogelstein speaks about what the past four decades of research has taught us about the mechanics of cancer, what genomics and molecular biology have taught us about it and how all of this information might best be exploited to address the challenges posed by cancer.
Dr. Bert Vogelstein is a pioneer in cancer genetics. As early as 1988, his research on colorectal cancer was transforming when he proposed that cancers result from the gradual accumulation of mutations in specific cancer-causing genes (oncogenes) and tumor suppressor genes.
Bert Vogelstein, MD. Investigator • 1995-Present. Dr. Vogelstein is the Clayton Professor of Oncology and Pathology and co-director of the Ludwig Center for Cancer Genetics and Therapeutics at the Sidney Kimmel Comprehensive Cancer Center of Johns Hopkins University School of Medicine.
